Cost‐utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|100|3|264-272

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.100, Iss.3, 2018-03, pp. : 264-272

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab Therapy in Cutaneous Infiltration of Chronic Lymphocytic Leukaemia

Acta Haematologica, Vol. 130, Iss. 1, 2013-02 ,pp. : 47-51

Karger

Access to resources Recommend Favorite

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy – the MD Anderson Cancer Center experience

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 2, 2015-10 ,pp. : 281-284

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 2015-10 ,pp. : 281-284

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 40-49

John Wiley & Sons Inc

Access to resources Recommend Favorite

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

By Kielhorn Adrian Porter Duncan Diamantopoulos Alexander Lewis Gavin

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2639-2650

Informa Healthcare

Access to resources Recommend Favorite